Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

CDK inhibitors; Breast cancer; Palbociclib Inhibidors de CDK; Càncer de mama; Palbociclib Inhibidores de CDK; Cáncer de mama; Palbociclib Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Bellet Ezquerra, Meritxell, Ahmad Diaz, Faten, Villanueva, Rafael, Valdivia Vadell, Carolina, Palomino-Doza, Julián, Ruiz, Ada, Azaro Pedrazzoli, Analía Beatriz, Aguilar Company, Juan, Martín Pérez, Anastasio, Escriva de Romaní Muñoz, Santiago Ignacio, Reyes López, Victoria, Alcalde Rodrigo, Maria, Ruiz Camps, Isabel
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino Acids, Peptides, and Proteins aminoácidos, péptidos y proteínas Breast Neoplasms CHEMICALS AND DRUGS COMPUESTOS QUÍMICOS Y DROGAS Cyclin-Dependent Kinase Inhibitor Proteins DISEASES Drug Interactions drug therapy ENFERMEDADES fenómenos farmacológicos fenómenos farmacológicos y toxicológicos fenómenos fisiológicos FENÓMENOS Y PROCESOS interacciones farmacológicas Intracellular Signaling Peptides and Proteins Mama - Càncer - Quimioteràpia Medicaments - Interacció neoplasias neoplasias de la mama neoplasias por localización Neoplasms Neoplasms by Site Other subheadings Otros calificadores Peptides Pharmacological and Toxicological Phenomena Pharmacological Phenomena PHENOMENA AND PROCESSES Physiological Phenomena proteínas inhibidoras de cinasas dependientes de ciclinas péptidos péptidos y proteínas de señalización intracelular Quinases dependents de ciclina - Inhibidors therapeutic use tratamiento farmacológico uso terapéutico
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	CDK inhibitors; Breast cancer; Palbociclib Inhibidors de CDK; Càncer de mama; Palbociclib Inhibidores de CDK; Cáncer de mama; Palbociclib Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.